Spots Global Cancer Trial Database for [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer

Official Title: [Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (ACCEL)

Study ID: NCT06229366

Conditions

Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Biochemically Recurrent Prostate Carcinoma

Interventions

[Ac-225]-PSMA-62 (mCRPC)

[Ac-225]-PSMA-62 (BCR)

Study Description

Brief Summary: ACCEL is a multicenter, open label phase I/II study of \[Ac-225\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.

Detailed Description: The primary aim of the phase I study is to evaluate the safety and tolerability of \[Ac-225\]-PSMA-62 to determine recommended phase II doses for patients with mCRPC and BCR prostate cancer. The aim of the phase II study for patients with mCRPC is to evaluate the efficacy of \[Ac-225\]-PSMA-62.